Saturday, February 21, 2015

Update for Lottery Ticket Basket Strategy as of 2/20/15/Bought Back as Lottos: 50 GST at $2.53 and 50 TTI at $4.94

The last update for this basket was published on 12/19/14: Lottery Ticket Basket as of 12/19/14/Sold QLGC at $11.92/Bough SKIS at $7.4 

The Lottery Ticket Basket Strategy will use a deep contrarian value strategy appropriately characterized as catching a falling knife. A common criteria for stock purchased in this basket is a smashed stock price.

See 2004 Study By the Brandeis Institute: Falling Knives Around the World 

Selections are made primarily on statistical criteria including price to book, price to sales, forward P/E, cash per share and/or free cash flow. I spend anywhere from thirty minutes to an hour researching a potential purchase prior to purchase.

For many selections, I may be pessimistic about the firm's future, but not as pessimistic as the market. I will also occasionally see a ray of light at the end of a dark tunnel.

Since I expect failures, which are inevitable and unavoidable in this kind of approach, I limit my exposure to $300 per stock plus any prior trading profits. 

After experiencing some success with this strategy, I now have a requirement that my total investment in all LT holdings can not exceed my total realized gains for this basket strategy. My total exposure is substantially below my net realized gain number, so I currently have a lot of available capacity to expand this basket under this particular risk control rule.

The name of the strategy aptly describes the risk. It is somewhat analogous in many cases to playing a hand of blackjack for the purchase amount knowing that the card count favors the house. It is a form of entertainment and an alternative to a casino visit.

Based on the results to date, this strategy is far more likely to produce positive results than playing Blackjack, even with the LB's skill at the tables. The primary purpose of the LT strategy is to entertain Right Brain, let it swing for the fences with up to $300, and to keep the Nit Wit from interfering with Left Brain's management of Headknocker's portfolio.

Since the last update, I have bought the two selections discussed below and sold the following:

Bought as LT: 50 RFMD at $5.18-Sold 50 RFMD at $16.52-Total Realized Gain 206+% (12/30/14 Post)(snapshot of realized gain $551.08)

Bought: 100 MRGE at $2.48-Sold 100 MRGE at $3.54-Lottery Ticket Basket (1/7/15 Post)(snapshot of profit $90.24)

Snapshots of realized gains can be found at the end of the Gateway Post on this topic: Lottery Ticket Strategy: New Gateway Post

Net Realized Gains:  $14,789.62

Click to Enlarge: 


LOTTEY TICKET BASKET AS OF 2/20/15
Considering that the strategy started in 2009, and has usually had $5000 to $7000 devoted to it with the severe monetary limitations per stock discussed above, that is a decent return in context.

I have a few selections that appear to be making runs toward zero, a known hazard when the selections are falling knives.

Generally, I will keep the Lotto until it becomes really tight on whether the sale's proceeds will cover the brokerage commission. I have had several come back into good profits after collapsing in price, so I want to give these selections a lot of room to run to the downside before I pull the plug. When I pull the plug, the result is often a total loss.

I am after all dumpster diving when selecting Lottery Ticket purchases, and consequently expect to come up with nothing but garbage more than just a few times.  

Some of the selections have improved their circumstances sufficiently that I would no longer categorize a buy as a Lotto.

NPBC have already been promoted to the Regional Bank Basket Strategy, but I am keeping the 30 share lot bought as a Lotto in this basket.

ING, FCF and FCE/A no longer fit into the Lotto risk category. I have no interest in acquiring more shares, so they wallow in this lowly risk category. My largest unrealized gain is in Forest City shares.

ING recently resumed its common share dividend after eliminating it back in 2008. The company plans to pay out €.12 per share later this year and has committed to pay at least 40% of Ing Group's annual net profits in dividends. Dividend Policy & Payments | ING

A number of recent Lotto purchases were bought to generate income and are unlikely to produce significant percentage capital gains.

Some Unrealized Gains as of 2/20/15: 

FCE/A: 114.8%
ING:       59.92%
IRDM:   36.49%
FCF:       37.96%
NPBC:   31.44%
FHN:     24.17%


Most of my discussions of Lotto purchases are cursory. I am merely summarizing some points viewed as relevant to the Lotto characterization (e.g. risks) and a ray of light for possible capital appreciation.

1. Bought 50 Shares of Gastar Exploration at $2.53 (see Disclaimer): 

Snapshot of Trade:

2015 Bought 50 GST at $2.53

The shares closed at $3.06 last Friday.

Gastar Exploration Inc. (GST) is a small E & P company: Operations

SEC Filings

Gastar has slashed its 2015 capital budget to $103M, of which $79M is budgeted for drilling, completion and infrastructure costs. GST claims that it increased it proved reserves 87% to 102.1M barrels of oil equivalent during 2014. About 53% of those reserves are in liquids and the remaining portion consists of natural gas. The pre-tax "present value of future cash flows of those reserves discounted at 10% (P-V 10) grew 67% to $988.7M. GST Reserves and Budget Update

The first effort at formulating a 2015 budget, made in September 2014, arrived at a $257.3M number, GST 2015 Capital Budget and Guidance That budget was reduced to $173M when Gastar announced third quarter results: GST 3Q14 Financial Results

In September 2014, Gastar sold 17M shares at the public offering price of $6.25, with the usual over allotment option granted to the underwriters who paid Gastar $5.984375 per share. Prospectus That was very fortunate timing for GST. The shares thereafter declined by almost 60% to my $2.53 purchase price.

The hedges in place as of 9/30/14 are summarized starting at page 16 of the 10-Q. I have no qualifications to discuss hedges.

Gastar reported third quarter net income available to the common shareholders of $9.8 or $.15 per share. Revenues before hedging increased by 46% to $35.1M. Revenues from liquids represented about 80% of 3rd quarter revenues. Average daily production was 9.8 thousand barrels of oil equivalent. GST 3Q14 Financial Results

Results-Earnings Call Transcript | Seeking Alpha


I previously made a successful round trip in Gastar shares. Sold 100 GST at $4.1 (11/25/13)(snapshot of profit $126.09)-Bought 100 GST at $2.68 (7/29/13 Post)

A casual reader would notice that I bought back 50 shares rather than my previous 100 share buy at a higher price. Gastar is a small E & P company with how shall I say this politely-"uncertain prospects".

I also own 50 shares of GSTPRB, a 10.75% coupon equity preferred stock and that coupon says a lot about GST's risks. Bought: 50 GSTPRB at $25.3 (12/13/13) During the recent cascading crude oil decline, GST.PB cratered to a low near $18. I actually have a tax profit in the shares due to the dividend being classified as ROC.

The company has two equity preferred stocks:

Gastar Exploration Inc. 8.625% Cumulative Preferred Series A (GST.PA)Prospectus
Gastar Exploration Ltd. 10.75% Cumulative Preferred Series B (GST.PB)Prospectus

There is also $325M outstanding in a 8.625% lien bond maturing in 2018: Bond Detail; Prospectus

While the prospectus refers to that bond as "senior secured", it is in effect a second lien bond subordinate to the first lien credit facility.


GST seems to have taken prudent steps given the current energy price environment. For its size, GST is leveraged with a lot of debt due in 2018, and also has some high cost preferred stocks. The company will need a significant recovery in prices during 2015, or early in 2016 at the latest, in order for the stock to have a decent shot at returning to that $6.25 September stock offering price. There is at least a chance, and I really can not put odds on it, that GST's share price will reward my small bet placed with the house's money.

GST's stock price certainly fits the Lotto criteria of being smashed to smithereens. The stock closed at $8.99 last June and was bouncing near $2 during January: GST Interactive Stock Chart

The chart highlights risks. The company discusses risks incident to its operations starting at page 26 of its last Annual Report: GST- 2013-10K

2. Bought Back Tetra Technologies (TTI) at $4.94 (see Disclaimer): 

SEC Filings for TTI

Snapshot of Trade: 


I have bought and sold this stock as part of the LT basket: Sold 50 TTI at $9.97 (2/25/13 Post)(snapshot of profit=$140.89)-Bought 50 TTI at $5.98 (10/16/12 Post)

When playing small ball, harvesting a good percentage profit with a short term trade and then buying the shares back at a lower price is the equivalent of a home run.

Tetra Technologies (TTI) is an oil service company that is focused on "completion fluids and associated products and services, water management, after frac flow back, production well testing, offshore rig cooling. compression services and equipment, and selected offshore services including well plugging and abandonment, decommissioning, and diving". 2014 3rd Q 10-Q at page 6.

The company is organized into four divisions: Fluids, Production, Testing and Compression.

Products & Services


TTI has a small oil and gas E & P business, known as Maritech Resources, that is causing the company to report losses. Martiech sold most of its oil and gas properties in 2011 and 2012, and is incurring abandonment and decommissioning costs in its remaining operations. (e.g. $222.25M of 79% of Martitech's proved reserves to Tana Exploration).


An increase in liabilities associated with the production exit required a "significant increase" in Maritech's liabilities during the 2014 third quarter. The cash burn problems associated with those activities since 2010 is described at page 5 of the last earnings call transcript. From what I am able to gather, the work is just almost complete.

Part of the compression business segment is through TTI's interest in a publicly traded MLP CSI Compressco L.P. (CCLP), a company the provides natural gas compression in the U.S.

TTI is CCLP'S general partner and owns 44% of the common units. The market cap of CCLP was about $552M at a 2/20/15 closing price of $16.66. TTI's common unit ownership interest in CCLP is about $243M as of last Friday, assuming no change in the ownership interest stated at page 11 of the 9/30/14 10-Q. TTI's market cap at last Friday's closing price of $5.12 is about $408M.

If I subtracted the value of TTI's CCLP interest from its $408M market cap, the remaining businesses are valued at $165M. Possibly, that math may interest an acquirer using the temporary decline in energy prices to expand their business footprint on the cheap.

TTI had $340M in long term debt  and $90.288M of short term debt as of 9/30/14. The maturity schedule is set forth at page 13 of the 10-Q. There is a 6.56% senior note in the principal amount of $90M maturing in April. A 5.9% senior note in the principal amount of $90M matures in April 2016 with three other senior notes maturing in 2017 and 2020. The amounts and dates of those maturing senior notes is worrisome given TTI's  recent operating numbers.

The company reported a loss of $.13 per share for the 2014 third quarter, compared to a profit of $.15 per share in the 2013 4th quarter. The loss was attributed to continued losses in the Maritech segment ($23M pre-tax), "transaction costs" and "unusual items". SEC Filed Press Release Those three categories nipped earnings after tax by $.25 per share.

Q3 2014 Results - Earnings Call Transcript | Seeking Alpha

The consensus E.P.S. estimates, which appear to be ex-item numbers, is for $.31 in 2015: TTI Analyst Estimates

TTI Key Statistics (YF at $5.12 and Through 9/30/14):
Price to Book: .76
Price to Sales: .41
Total Cash: $36.22M

The P/B and P/S ratios are consistent with Lotto selection criteria.

Two hedge funds own more than 4% of the stock, based on filings as of 12/31/14:

Daruma Capital: 8.18% Schedule 13-G
Fuller & Thaler Asset Management - Behavioral Investing: 4.26%

The T. Rowe Price funds owned 6.43% in the aggregate: TTI Major Holders

 There has been recent insider buying: TTI Insider Transactions

One columnist included TTI as one of 10 oil service companies "ripe to be taken over". The stock price was then $8.36 (11/14/14).

The stock was selling at over $13 last April: TTI Interactive Stock Chart Just another awful looking chart inherent in Lotto stock selections.

The company discusses risks incident to its operations starting at page 11 of its last Annual Report: 10k-2014 

Tuesday, February 17, 2015

Sold 100 of 200 DPG at $20.74/Sold Roth IRA: 100 PNNT at $9.53 and 70 ARCC at $16.87-Balancing Risks and Rewards/Bought 50 RHHBY at $32.99/Bailed on SD 2020 Bond-Sold at 74.69-Bought at 65

Stable Vix Pattern (Bullish):
Links to SeekingAlpha Instablog, Articles and Comments:

South Gent's Instablog | Seeking Alpha

South Gent's Articles | Seeking Alpha

South Gent's Comments | Seeking Alpha

*********************
Recent Developments:

As explained in this Bloomberg article, it may be several more months before U.S. crude oil production starts to decline.

The EIA reports weekly field U.S. crude oil production. For the week ending 2/6/15, production hit an all time record of 9.226 million barrels per day.  Weekly U.S. Field Production of Crude Oil (Thousand Barrels per Day)

Individual tax receipts are moving higher, suggesting that employees are starting to see more wage increases.

The German central bank released last Monday an upbeat report on the German economy. Their analysis can be found starting at page 7: Monthly_Report The report is summarized in a MarketWatch article.

Singapore’s economy grew at a 4.9% annualized rate in the 2014 4th quarter. My primary exposure to Singapore's stock market is my 200 share position in iShares MSCI Singapore ETF (EWS). I recently added 100 shares. Item # 3 Added 100 of the Stock ETF EWS at $12.8 (1/19/15 Post)

Zurich Financial (ZURVY) reported somewhat disappointing results. Zurich released its annual results 2014

In response to that earnings' release, the ADR price declined $1.29 to close at $32.49 (2/12/15). One ADR equals .1 ordinary shares priced in CHFs. The ordinary shares closed at CHF303.2, down 9.7 or 3.1%. Zurich stock information and share price | Zurich Insurance

The Zurich Board proposed a 17CHF per share annual dividend to be paid out of capital reserves. In the past, the sourcing of payment from capital reserves has avoided the Swiss withholding tax due to the dividend being classified as a return of capital.  So that will be 1.7CHF for my ZURVY shares. The actual value will be determined when the CHFs are converted into USDs. If that was done today, which of course will not be the case, the value would be $1.8264:

 
If I am right about this dividend being treated as a ROC due to its sourcing, then my cost basis will be reduced again by the amount of the dividend, which will bring the total adjusted cost per share near $17, even though I bought shares in 2012 at $24.72. BOUGHT 100 ZFSVY at $24.72 (symbol later changed to ZURVY) I took a snapshot of my adjusted cost basis, which is currently $19.21, in the introduction section to this post: ZURVY

***********************

1. Sold 100 DPG at $20.74  (see Disclaimer):

Snapshot of Trade:

2015 Sold 100 DPG at $20.74


Selected Highest Cost Shares for Disposition: 




Snapshot of Profit:


2015 DPG 100 Shares +$200.07
Item # 7 Added 100 DPG at $18.58 (2/3/14 Post)

There was a ROC adjustment to the cost basis primarily due to DPG's ownership of MLPs.

4 Quarterly Dividends ($.35 per share) Received: $140

Total Return = $340.07 or 18.23% (holding period 12+ months)


I still own 100 shares in a taxable account: Item # 1 Bought 100 of the CEF DPG at $17.3 (12/29/12 Post);

Total Realizing Share Profits (excluding dividends)= $603.14

Security Description: The Duff & Phelps Global Utility Income Fund  (DPG) is a leveraged closed end stock fund that invests in electric, gas and water utilities, telecommunication companies and MLPs.


CEFConnect for DPG


Last SEC Filed Shareholder Report:  Duff & Phelps Global Utility Income Fund


DPG Page at Morningstar (currently rated 3 stars; leveraged at 22.5%; ROC support for the dividend originating mostly from ROC MLP distributions)

Quarterly dividends have paid recently at $.35 per share. Duff & Phelps Global Utility Income Fund Inc. (DPG) Dividend Date & History

The risks are fairly typical for a leveraged stock closed end sector fund that buys securities worldwide. There will be some currency risks, the normal CEF risks (e.g. expansion of discount after purchase), price risk due to valuations of owned securities, interest rate risks to the prices of bond substitute securities, and the risks associated with leverage (e.g. borrowing costs, buying assets which decline in price with borrowed money adding to the woes, etc.)

Rationale: The paring of this position is consistent with three themes: (1) a concern about the negative impact on bond substitutes flowing from a rise in interest rates; (2) the likelihood of increases in the federal funds rate over the next several years that will raise the borrowing costs of leveraged closed end funds; and (3) what I regard as a significant overvaluation in utility stocks.

As of 2/13/15, the Utilities Select Sector SPDR ETF (XLU) had a forward estimated P/E of 17.4 and a dividend yield of only 3.32%. The estimated 3 to 5 year E.P.S. growth rate was 4.86%. The P.E.G. ratio is elevated due to the low growth rate and high P/E.

This sector is vulnerable to a correction precipitated by even a modest rise in rates that diminishes the allure of a 3.32% yield and further calls into question such a high P/E for a sector growing earnings only in the low single digits.

A P.E.G. of 2  to 2.5 would be closer to a fair value range with rates rising, an estimated 3 to 5 E.P.S. growth rate of 4% to 5%, provided the rise in rates ebbs below the average historical norms.

I go into more detail about the rationale in a recent SA Instablog: A Word Of Caution About New Purchases In The Utility Sector - South Gent | Seeking Alpha


The Vanguard Utilities ETF (VPU) has another set of data that is even more concerning than the XLU valuation information:

As of 1/31/15,  this Vanguard fund owned 78 stocks, with a P/E of 20.8 times and a 2% growth rate. Portfolio & Management That P/E and growth rate simply does not compute for the LB who views it to be at best irrational, a description used whenever it decides to be pleasant about something viewed as nutty.

2. Downsized BDC Exposure in Roth IRA after Reassessing Risks and Rewards: Sold 100 PNNT at $9.535 and 70 ARCC at $16.87 (see Disclaimer):

Snapshot of Trades:





Snapshot of Gains:

Total +$117.74

Rationale: I have repeatedly said that externally managed BDCs exist to enrich the managers rather than to benefit the mostly individual investors who are lured into buying shares. The honey used to attract investors is a high dividend yield in a world without risk free yield.

After the recent dividend slashes at both PSEC and FSC, I decided to start lowering my overall exposure to BDCs in the retirement accounts.  I am going to assign any new purchases to the lowly lottery ticket category for BDCs that are not presently owned. I may elect to average down with a few small odd lot buys in PSEC and FSC only, unmindful of the First Law of Holes which I referenced in a recent SA comment involving the horrific actions of that BDC. Time To Accumulate Fifth Street Finance Shares? - Fifth Street Finance (NASDAQ:FSC) | Seeking Alpha I have not yet averaged down on FSC due to the most recent price carnage inflicted on shareholders by Fifth Street's managers. Individual investors reading recent SA articles might be blinded by the current discount to net asset value and ignore or lightly regard the reasons for that lowly status.

3. Bought 50 Roche (RHHBY) at $32.99 (see Disclaimer):


Snapshot of Trade:



The ordinary shares closed at CHF 245 -.80. on the day of my purchase.

ROG:SIX-Bloomberg

1 ADR = .125 Ordinary Shares

RHHBY Roche Holding

.125 Ordinary Shares=  CHF 30.625

Conversion Value for 1 ADR: $33.0474



Company Description: Roche Holding AG ADS (RHHBY) is one of the world's largest pharmaceutical and diagnostic companies. The company is based in Switzerland with a significant presence in the U.S. through its U.S. wholly owned subsidiary Genentech.

Roche will be adversely impacted in its reported revenues and sales due to the rise in the Swiss Franc. About 18% of Roche's costs are in CHFs, and the company has no plans to move existing operations to lower cost countries. Reuters A continuation of the CHF at its current level is anticipated to reduce core earnings by 9%.

Roche shares have declined over the past year in part due to several pipeline drug failures. New drug treatments for Alzheimer's disease, schizophrenia and two other drug candidates (ALECARDIO aleglitazar  and the lung cancer drug Onartuzumab) due to safety and/or efficacy issues. As noted in the prior link regarding the lung cancer drug, the unexpected Phase III may be reflect a poor trial study design.

In 2009, Roche made an important acquisition by agreeing to acquire the remaining 44% of Genentech shares that it did not own for $95 per share or $46.8 B. Roche had acquired majority control of Genentech in 1990 for $2.1B. Genentech is now a wholly owned Roche subsidiary. Bloomberg

Some of the important Genentech drug discoveries include the following cancer drugs, many of which are well known to non-stock investors:

Avastin: metastatic colorectal cancermetastatic kidney cancerlung cancer,

Gazya:  chronic lymphocytic leukemia,

Herceptin: breast cancer,

Rituxan: Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia,

Tarceva: Non-Small Cell Lung Cancer and

Zelboraf: (metastatic melanoma)

Other Genentech discoveries include Lucentis (wet macular degeneration), Tamiflu, and Xolair (allergies)

Lucentis is sometimes to referred to as a cosmetic version of the Avastin molecule.  Lucentis is about 50 times more expensive and both drugs cost about the same to manufacture. Eye doctors will often use avastin off-label to treat wet macular degeneration rather than Lucentis. It may be more profitable for the doctors to use Lucentis however. As noted in the preceding linked article published by the Washington Post, Medicare has to pay for both drugs. Lucentis has been approved for the treatment of wet macular while the company has refused  the FDA's entreaties to seek approval for Avastin's use in that treatment. While I do not remember the details, Avastin was approved as a cancer treatment by the FDA, and its effectiveness was due to cutting off the blood supply growth to tumors. Patients who were taking the drug for cancer noted an improvement in their vision. Some eye doctors started to inject Avastin directly into the eye to shut down or reduce abnormal blood vessel bleeding that was destroying the macular (the center of the retina) and causing loss of eyesight.

A new drug for wet macular degeneration, Eylea, has been approved by the FDA.

Roche currently does not expect biosimilar competition for its Herceptin product before 2017.

I took a snapshot of drug sales by product to highlight Genentech's importance to Roche:


Page 12:  Roche 2014 Financial Report.pdf

As shown in the preceding table, two recently approved cancer drugs, Perjeta 2012) and Kadclya   (2013) are rapidly increasing sales. Both are breast cancer drugs.

FDA approves Perjeta for type of late-stage breast cancer (2012)

FDA approves new treatment for late-stage breast cancer (2013)

FDA approves Perjeta for neoadjuvant breast cancer treatment (2013)

Sales of Pegasys, an approved treatment for hepatitis B and C, are declining due to competition from new treatments.

About 75% of Roche's revenues come from biologics which are less susceptible to traditional generic competition.

Roche's in vitro diagnostic business has about a 20% global market share.

2014 Annual Report.pdf

The annualized total return for the ADR shares was 13.63% starting on 8/20/2003 through 2/14/15. Total Return

RHHBY currently has a 4 star rating by Morningstar with a fair value estimate of $35. Zacks has an underperform rating and a $31 price target.

I also read several recent press releases including the  following, with the first probably being the most important:

U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer

FDA approves Roche's Lucentis for treatment of diabetic retinopathy in people with diabetic macular edema

Roche's Phase III study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin's lymphoma


Chart: RHHBY is currently selling below its 50, 100 and 200 day simple moving average lines. RHHBY Interactive Stock Chart 

As shown in that chart, the shares have been in dive mode since closing at $37.92 (12/1/14). The USD priced shares received a lift when the Swiss National Bank ended its Euro peg that immediately caused the CHF to rise in value against the Euro and the USD. The rise in the value of the CHF flows through into the pricing of the USD priced ADR. However, due to the decline in the ordinary shares, this currency related gain was muted and short lived, as the ordinary shares priced in CHFs declined in value as shown in this one year comparison chart:

One Year Comparison Chart CH:ROG (Blue Line) vs. RHHBY




The Swiss stock market declined significantly in value when the Swiss National Bank ended its Euro peg. The stronger Swiss Franc will have a negative impact on reported earnings. That decision was announced on 1/15/15. The currency related rise in the ADR shares was higher than the percentage decline in the ordinary shares which is why the RHHBY line chart goes up that day as the ordinary share price plunged in value.

Dividend History: I could only find at Roche's website a chart depicting its dividend history since 2002:



I consequently do not know the dividend amounts prior to 2002.

In its "Investor Update" dated 1/28/15,  Roche states that is board approved a 3% dividend increase to 8 Swiss Francs, the "28th consecutive year of dividend growth".

The chart does, however, show a significant slowing in the dividend growth rate. It looks like about 1.5CHF per share was paid in 2002. The percentage increase to 8 CHFs would be huge at 433.33% over a 13 year period, Calculate Percent Increase, but the last increase was only 3%.

Like many European companies, Roche pays its dividend annually.

The 8 Swiss France for the ordinary shares translates in a dividend of 1 CHF per ADR share.

The value of that dividend will be determined when the actual conversion from CHFs to USDs takes place. If the conversion occurred on 2/10/15, the date of my share purchase, the value would be about $1.0815. For purposes of illustration only, that dividend value would result in a dividend yield of about 3.28% at a total cost of $32.99 per share.

Switzerland's Withholding Tax: 

Switzerland will withhold a 15% tax on that amount. When held in a taxable account, a U.S. taxpayer can recover all or part of a foreign dividend tax as explained in this Schwab article.

A taxpayer may run into a problem recovering all of the foreign taxes when the amount of foreign tax paid exceeds $300 for a single person and $600 for a married couple. A credit can be claimed up to those amounts without filing out a somewhat complex IRS form 1116. Accountants may not mind filling out that form since it just adds to the bill. It gives me a headache.

That form has to be filled out when claiming more than those limits as a credit. The form will limit the foreign tax credit "to the lesser of the amount of foreign tax paid or the U.S. tax liability on the same income". This would become relevant for a taxpayer who wants to claim more than the foregoing limits, but who is in a marginal tax rate of less than 15% when the foreign dividend income tax rate was 15%. I would emphasize that I am just giving a common sense explanation of the material contained in that Schwab document. I am certainly not a tax expert, and I am not giving anyone tax advice here. It is important, however, to at least grasp the essential elements explained in that Schwab article to make an informed investment decision when buying dividend paying foreign stocks.

Recent Earnings Report: I would generally describe the recent earnings report as unimpressive, which partly explains my relatively small initial purchase. For the full year, Roche reported core E.P.S. of CHF 14.29, missing the consensus estimate of CHF 14.7. On a constant currency basis, core E.P.S. and revenues advanced about 5% Y-O-Y. That number is expressed in the abbreviation CER (constant currency rates) in the following table:





Page 5 Finance Report.pdf

Free cash flow decreased about -1% in 2014 to CHF5.322B. (pages 10 and 33)

Roche expects 2014 revenues to grow in the low-to-mid single digits based on constant exchange rates. Core earnings per share are targeted to grow faster at CER. Roche Press Release-"Roche delivers solid results in 2014"

Rationale: I would not be buying Roche stock without Genentech being in the fold. I simply have more confidence in the ability of Genentech researchers to discover new drugs, and the value of a drug company long term will be driven by internal innovation rather than the Pfizer approach to drug discovery.

I also want more exposure to assets priced in Swiss Francs without having to convert my USDs into CHFs. I may pursue that option in a few years, but I am content now in expanding my ownership of U.S. traded Swiss stocks whose value will be determined in part by the value of the CHF/USD exchange rate.  I have far more confidence in the CHF as a store of value long term than the USD.

While Roche's dividend growth has slowed some, the company does have a long track of raising its dividend. The pace of future dividend increases will depend on drug discoveries rather than existing products.

There is a fairly robust pipeline of new drugs currently in trials or new use FDA filings for existing drugs: Roche-Pipeline and Pipeline Summary.pdf (new molecular entities at pages 79-81). However, I did not see a number of potential near term catalysts in the pipeline.

Risks: Based on the 2015 E.P.S. estimate of CHF 14.02, Bloomberg, the forward P/E is about 17.37 based on last Friday's closing price of CHF243.6. I view that number as being in the upper end of my fair value range for Roche. I would therefore anticipate slower capital appreciation unless the E.P.S. growth rate accelerates. Without the CER adjustment, the 2014 E.P.S. was CHF 14.29, virtually unchanged from the CHF14.27 reported in 2014.




I will focus on earnings and revenues expressed in constant currencies. Core E.P.S. grew only 5% in 2014 based on the constant exchange rate.

The recent pipeline failures calls into question Roche's ability to successfully discover new treatments that have both efficacy and safety.

Future Buys and Sells: Until I see better results in CER, I am not likely to buy more shares unless there is a price drop to below $30 without any material adverse event causing the decline.

I have a larger position in Novartis and have a far more favorable opinion of NVS than of Roche, though I do not find NVS shares attractive at over $100 per share. Dividend Growth Strategy: Novartis - South Gent | Seeking Alpha

Novartis owns about 53.3+M Roche shares:  Roche - Major Shareholders

4. Sold 1 Sandridge 8.75% Senior Unsecured Bond at 74.69 (see Disclaimer):


Snapshot of Profit:

2015 Sold 1 SD Bond +$73.68 
Bought 1 Extremely High Risk Sandridge Energy 8.75% Senior Bond Maturing 1/15/2020 at 65 (12/17/14 Post)

Net Interest: $14.58

Total Return: $88.27

Security Description: This is an unsecured senior bond issued by the E & P company SandRidge Energy (SD), whose common shares are hovering near $2 after rallying substantially in percentage terms from a mid-January 2015 low around $1.18.

FINRA Page for SD 2020 Bond: Bonds Detail

Rationale: When I bought this bond, it made me uncomfortable. I referred to this buy as analogous to playing a hand of blackjack for $650, which is actually beyond the OG's limit of $300.

To relieve the anxiety, which needs to be lessened for senior citizens like the OG who has barely recovered from the angst permeated Near Depression period, LB decided to harvest the 10%+ annualized total return rather than listen to more moaning and groaning from the OG.

Friday, February 13, 2015

Update for Regional Bank Basket as of 2/13/15 /Added 100 FNLC at $16.81/Recent Earnings Discussions for BHB, FNB, FFBC, NPBC, WTBA and BKSC Only

This strategy is explained in my Gateway Post on this topic:

Snapshots of realized gains and losses can be found at the end of that post.

Last Update: Stocks, Bonds & Politics: Regional Bank Basket Update as of 1/2/15

This basket will be updated randomly, usually within 1 to 2 months after the last update.

The dividend yield showed in this table is calculated by Yahoo Finance based on yesterday's closing prices. My dividend yield for each position will be different based on my total cost numbers. In most cases, with FNFG and VLY being notable exceptions, my dividend yield will be higher.

Dividend Yields 5% or higher: Based on Total Cost
NYCB: 8.44%
WASH: 8.34%
UBSI: 7.66%
FNLC: 5.38%
CBU: 5.15%
CCNE: 5.%

I am not tracking reinvested dividends in the following table. The unrealized gains per holding do not include reinvested dividends.

Over the life of this basket strategy, I anticipate that the dividends will provide 40% to 50% of the total return. I am generally keeping my total exposure between $40,000 to $50,000.

After a number of adds, I am now over my minimum $40,000 allocation after a bout of profit taking in 2013.

SPDR S&P Regional Banking ETF (KRE) Total Returns (NAV):
2009:  -21.92%
2010: +20.65%
2011: -  5.98%
2012: +16.91%
2013: +47.34% 
2014: +1.85%

In 2013, my dividend total from this basket totaled $1,932,93, up from $1,896.25 in 2012 and $1,660.57 in 2011. My dividend total for 2014 was $1,831.19, down slightly from 2013. The decline was not due to dividend cuts but to the lower exposure during the 2014 first half after a bout of profit taking during 2013.

Regional bank stocks churned in price during 2014 as interest rates started to go back down. One of the regional bank ETFs, KRE, closed at $40.61 on 12/31/13 and closed the year at $40.70 -0.44 (-1.07%). SPDR S&P Regional Banking ETF Chart

I have bought and sold that low yielding ETF: Bought Taxable Accounts: 50 KRE at $39.55 (9/20/14 Post)- Sold 50 KRE at $41.35 (1/15 Post)

Net Interest Margin (the honey pot for regional banks)



3.09% 2014 3rd Quarter

Net Interest Margins-Forbes Article November 2014 
"Big Banks Poised to Ride Rising Rate Tide" (9/2014 WSJ)


It is just tougher to grow earnings when the net interest margin narrows rather than expands.

The abnormally low rates benefited banks some when deposit yields were repriced down, but even 5 year bank CDs taken out in 2008 at higher rates have now matured, and the positive impact of that repricing is no longer present to any meaningful degree. 

Instead, the decline in rates for loans simply compresses net interest margin. When rates were rising in 2013, regional bank stocks were in an uptrend based on the common belief that higher intermediate and long rates would be a net positive for them, particularly when short terms were likely to remain near zero through mid-2015 and then rise slowly and modestly in 2016-2017. The rate spike starting May 2013 and ending in December 2013 impacted intermediate and long term rates. Short term rates remained anchored by ZIRP. 



In 2014 and so far this year prior to 2/2/15, intermediate and long term rates had been drifting down. Prices for regional bank stocks have been under selling pressure during that period of declining rates, a trend that may be aggravated when the FED starts to raise the federal funds rates that will increase the rates paid on deposits and thereby placing additional downside pressure on net interest margins. If the FED increases the FF this year by .5% and intermediate and long term rates remain stable at current levels, that would be unfavorable for regional bank stocks. 


A repeat of the rate rise between 5/2/13 and 12/31/13 would likely be a positive for regional bank stocks due to a common belief that regional banks are net beneficiaries of an interest rate rise. 


The yields shown in the table below are calculated by Yahoo Finance based on today's closing prices rather than at my total cost per share.

Loan Losses and Charge Offs:

Another important component underlying bank earnings involves loan losses and charge-offs for bad loans. The trends here are favorable. It does not help a bank to see the net interest margin increase from 3% to 3.5% and then to have the non-performing loans to total loans increase from 1% to 3%.


NPL Ratio

Charge Off Ratio

Ideally, I want to see the net interest margin going up while the NLP and charge-off ratios are declining. So far, the regional bank investor is seeing two out of three major metrics move in a favorable direction. The key now is for net interest margin to expand.

Interest rates have been moving up since 2/2/15, probably in response to recent positive economic data, particularly the recent jobs report, in the context of abnormally low interest rates consistent only with a long term Japan Scenario for the U.S.

Transactions Since the Last Update: I discuss adding 100 FNLC in Item # 8 below.

Bought Back TRMK at $22.25-Regional Bank Basket Strategy (1/24/15 Post)

Sold 315+ TRST at $6.92 (1/11/15 Post) 

Net Realized Gains 2010 to Date: $17,957.38  (snapshots are in the Gateway Post) 
Dividends Received 2010 through 2014$8,454.91


Click to Enlarge


Regional Bank Basket as of 2/13/15
Last Friday was an uneventful day for this basket.  The ETF KRE rose $.14 or .35%.


Comparison Data From the St. Louis Fed:
Assets at Banks whose ALLL exceeds their Nonperforming Loans (I prefer a coverage ratio of  over 100% at the time of my initial purchase)(ALLL=Allowance for loan losses)

In the following section, I will just highlight a few of the recent earnings reports and discuss one recent purchase: 

1. National Penn (NPBC): For the 2014 4th quarter, NPBC reported adjusted net income of $26.5M or $.18 per share and further announced a stock repurchase program.


National Penn Bancshares, Inc. Announces $125 Million Share Repurchase Plan and Reports Fourth Quarter and Full Year 2014 Results

The performance numbers remain generally favorable:





NPL Ratio: .96%
Charge-Offs (annualized) as a Percentage of Total Loans: .12%
Total Capital Ratio: 15.16%
Tier 1 Ratio: 13.91%

National Penn Bancshares also declared a quarterly dividend of $.11 per share.

I am near break-even with my NPBC shares. I am reinvesting the dividend. Added 50 NPBC at $10.12 (9/29/14 Post); Added 50 NPBC at $9.85 (October 28, 2013 Post)Item # 2 Added 100 NPBC at $10.68 (8/17/13 Post)

I initially bought shares as a Lotto and still own those shares: Item # 1 RB Bought as Lottery Ticket 30 NPBC at $7.83 (4/26/11 Post)


2. FNB: F.N.B corporation reported 4th quarter net income of $37.3M or $.21 per share, up from $.18 in the year ago quarter. For 2014, E.P.S. was reported at $.8.

Except for the capital ratios, which are low for banks owned in my regional bank basket, the other performance ratios are okay (ROA) or good (efficiency ratio):




The following ratios are good in my opinion. I like to see a coverage ratio (allowance for loan losses to non-performing loans) over 100% when I purchase a bank stock.

NPL Ratio: .61%
NPA Ratio: .71%
Coverage Ratio: 172.06%
Charge Offs (annualized) To Total Loans: .17%


F.N.B. Corporation Reports Significant Revenue Growth and Record 2014 Net Income

I currently own 100 shares: Added 50 FNB at $7.8 (7/20/2010 Post); Bought 50 FNB at $11.25 (7/24/13 Post)

Prior to buying that 50 share lot in 2013, I had sold my highest costs lots using FIFO accounting and had kept the shares bought at $7.8 which I still own. Bought 50 FNB at $8.42 (May 7, 2010 Post) Bought 50 FNB at $9.36 (April 27, 2010 Post)-Pared FNB: Sold 50 at $10 and 50 at $10.18 (December 23, 2010 Post)

3. Bar Harbor (BHB): Bar Harbor Bankshares reported 2014 4th quarter net income of $3.1M or $.51 per share which included a net realized loss of $263K from the sale of securities, "reflecting the Bank's efforts to lower the duration of the portfolio and its overall interest rate risk profile".  While that loss does not sound like much, it does represent about 4.4 cents per diluted share for this small bank. I am not criticizing the decision to reduce duration and interest rate risk even if that requires taking a loss.








 
Bar Harbor Bankshares Increases Quarterly Cash Dividend 

I have not sold any BHB shares. The original purchase was a 50 share lot. Bought 50 BHB at $30 (2/10/12 Post) There was thereafter a 3 for 2 split giving me 75 shares. I added 25 shares after that split to bring my position up to 100 shares. Added to BHB at $26.34  (8/15/14 Post)

My total cost per share is currently $21.74. Regional Bank Basket Update as of 1/2/15 I have not reinvested the dividend.

4. Financial Institutions (FISI): For the 2014 4th quarter, Financial Institutions reported net income available to common shareholders of $7.6M or $.54 per share, up from $.43 for the 2013 4th quarter.


Net Interest Margin: 3.56%
NPL Ratio: .53%
Coverage Ratio: 272%
Efficiency Ratio: 58.59%
Charge Offs (annualized) to Total Loans: .32%
ROA: .98%
ROE: 10.96%
ROTE (return on average tangible equity): 14.12%

Capital ratios are okay, but would be at the low end for banks in my basket:




The consensus estimate, generated by 3 analysts, was for $.49 per share. FISI Analyst Estimates

Bought 50 FISI at $15.55; Added 50 FISI at $19.8

5. West Bancorp (WTBA): West Bancorporation reported 4th quarter net income of $5.8M or $.36 per share, up from .27 in the 2013 4th quarter.

The Texas Ratio is outstanding at 2.71%.

These numbers are excellent, except for net interest margin which is above average now, and all are moving in the right direction:





Bought 100 WTBA at $11.67 (6/29/13 Post)

6. Bank of South Carolina (BKSC): This small bank holding company is probably unknown to many investors who invest in this sector. There is no analyst coverage that I can find. As far as I can tell, I was the first person to write a SA article about this bank: Regional Bank Basket Strategy: Bought 50 Shares Of Bank Of South Carolina At $14.6-Bank of South Carolina Corp. (NASDAQ:BKSC) | Seeking Alpha


Bank of South Carolina reported net income of $1.191+M or $.26 per diluted share for the 2014 4th quarter, up from $.22 in the 2013 4th Q. The bank provides few details in its earnings press release. Earnings for the year increased by 7.9%. The 2014 diluted E.P.S. was $.96 up from $.91. ROA for the quarter was reported at 1.23%. ROE was given at 11.72%. The 10-Q, which will have more information, has not yet been filed.


7. First Financial Bancorp (FFBC): First Financial Bancorp reported 4th quarter net income of $18.6M or $.30 per share, up from $.07 in the year ago quarter. The 2014 4th quarter had several acquisition related items that are not expected to be recurring that reduced net income by $.02 per share. The Board declared a $.16 per share quarterly dividend.








I have taken some profits in FFBC shares and have a current average cost per share of $14.7. Item # 2 Added 30 FFBC at $14.24 (December 2012); Item # 2 Added 50 FFBC at $14.65 (June 2013 Post)

Pared Highest Cost Shares by Selling 55 FFBC at $17.31 (profit snapshot $110.59 LT) and Sold 57 FFBC at $17.03-Highest Cost Shares (profit $37.68)

8. Added 100 FNLC at $16.81 (see Disclaimer):

Snapshot of Trade:




This stock is lightly traded, and I used an All or None Limit Order.  On the day of my trade, the volume was 14,743 shares with a low hit at $16.81 and a high at $17. The 52 week high/low was then $18.54 and $15.52 respectively.

FNLC Historical Prices | First Bancorp, Inc (ME)

Company Description: The First Bancorp Inc.  (FNLC) is the bank holding company that owns the "The First" bank operating in Maine and  First Advisors (investments, trusts, financial planning, etc.)

The First Bank currently has 16 retail branches in Maine:

Pictures of the bank's branches can be found at The First Locations.

Most of the branches dot the Maine coastline in places like Calais, Eastport, Bar Harbor, Northeast and Southwest Harbor. There is a branch in Bangor.

At a $16.88 price, the closing price on 2/12/15, the trailing 12 month P/E is 12.32 and the dividend yield is 5%. FNLC Key Statistics

I just described two reasons for buying this stock.

FNLC SEC Filings

Company Website: First Bancorp

There are no analyst estimates that I could find.

The total annualized return was 9.26% between 7/14/1999 through 2/12/15. The calculator used to arrive at that number only has data going back to that start date.

The annualized total return for the S&P 500 was 4.397% between July 1999 through January 2015. There were of course two catastrophic stock market declines between those dates.

Prior Trades: I currently own 50 FNLC shares in another taxable account bought at $15.6 .


I have had one round trip trade. Item # 2 Sold 52 FNLC at $15.55 (6/15/2012 Post)(snapshot of profit $123.88)-Item # 3 Bought 50 FNLC at $12.79 (9/26/11 Post)

I was not then "favorably impressed" with recent earnings reports when I sold that odd lot back in June 2012. I have a slightly favorable view of recent earnings reports.


Dividends: FNLC is currently paying a quarterly dividend of $.21 per share or $.84 annually. At a total cost of $16.81, the dividend yield at that rate would be about 5%.

This company is one of the few that provides both the historical dividend rate and the dividend rate adjusted for stock splits and stock dividends.


On an adjusted basis, the quarterly dividend was at $.009 for the 1991 second quarter. The dividend has been increased by 2,233.33+% to the present $.21 per share rate, using an online calculator to compute the percentage increase. The annualized 10 year dividend growth rate is 9.17%.  Calculator,

I just described a third reason for buying the stock. Hopefully, the bank will return to more robust dividend growth.

There was a dividend cut from a split adjusted $.012 to $.009 in 1991 that coincided with a recession and the savings and loan crisis, one of the many prior banking debacles.

There have been a few extra dividends paid in the 4th quarter, but that has not been done since 1999. The dividend was not cut during the recent Near Depression period, but the quarterly rate remained unchanged at $.195 starting in the 2008 third quarter through the 2013 third quarter.

The First Bancorp: Dividend History

Last Earnings Report: The First Bancorp reported net income of $14.7 million, up 13.5% from 2013. E.P.S. rose 14.2% to $1.37 per share. E.P.S. for the 4th quarter declined to $.32 or down  $.01 Y-O-Y.

During 2014, loans increased by $41.2M or 4.7%.

Some Relevant Financials: 



"Net chargoffs in 204 were $2.3 million or 0.26% of average loans on an annualize basis, compared to $5.2 million or 0.60% of average loans in 2013".  The 2014 charge-off number is goo as is the trend down.

The net interest margin is on the low side for my regional bank stocks, but the bank did manage to increase it slightly to 3.1%. The efficiency ratio was good at 56.86% as of 12/31/14. I like to see that number below 60% which is my marker for efficient operations. It was important to me to see the NPL ratio trending down after accelerating into 2011. As of 12/31/14, the NPL ratio ha declined to .97% from 1.44% as of 12/31/13, so it is moving in the right direction at least for now. The dividend payout ratio is a little high at 60.14% but down from 65.42% as of 12/31/13 even with a dividend increase last year.

Capital ratios are good and can be found at page 67 of the 2014 third quarter 10-Q:

FNLC-Q/E 9/30/14 Form 10-Q

Historical Earnings-Near Depression Period: I am always interested in how a bank performed during the recent Near Depression and the slow recovery that has followed that near total collapse of the world's financial system. I have already mentioned one important metric. FNLC did not cut its dividend. I also want to know whether the bank remained profitable during the most significant economic downturn since the Great Depression. This will give me some insight into whether the bank is run by a bunch of cowboys or worst, the infamous Masters of Disaster that populate so many U.S. banking institutions,  or is operated with prudent risk taking.

I can find the relevant data by looking at one of the historical 10-K filings. I will generally pick the 10-K filed in 2012.

I took a snapshot of the relevant information found at page 21:



2007-2011 Results
The bank remained profitable between 2007 through 2011. The return on tangible equity numbers remained above 10%. Book value and tangible book value increased during the period. Non-performing loans to total loans (NPL Ratio) remained below 2% in 2008-2009. I then see what caused me to sell the stock in 2012. The NPL ratio accelerated to 3.21% in 2011 and E.P.S. declined to $1.14 in 2011 from $1.22 in 2009. The bank needed to be going the other way in those numbers with an ongoing economic recovery.


Rationale: I have already highlighted the reasons for buying more shares.

1. The P/E based on trailing 12 month earnings is reasonable at slightly over 12.

2. The dividend yield is about 5% at my purchase price, and the bank does have a history of growing its dividend.

3. The bank appears to be prudently managed based on its ability to earn a profit and to maintain its dividend during and after the worst financial crisis since the Great Depression. This gives me some confidence that the bank will weather less severe, future economic downturns which will occur. The only questions are when, how many, how long and how deep.

I would be satisfied with an annualized total return of 8% to 10% with the dividend providing more than 1/2 of that return.

Risks: The company summarizes risks incident to its operations starting at page 10 of its 2013 Annual Report.

With small banking institutions, results can be nicked significantly when a million dollar loan goes bad. I doubt that Jaimie Dimon is informed of a deteriorating credit of that size.

Regulatory expenses tend to knick the smaller banks more as a percentage of revenues and earnings.

Bank stocks will perform badly during a recession and potentially worse than the overall market.

Net interest margin has been a problem for all banks due to the abnormally low interest rate environment that has compressed their spread between interest costs and interest income.